BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalangood S, Zhu Z, Ma Z, Li J, Zeng Q, Yan Y, Shen B, Yan J, Huang R. Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics 2020;10:10078-91. [PMID: 32929335 DOI: 10.7150/thno.48711] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Nag S, Mandal A, Joshi A, Jain N, Srivastava RS, Singh S, Khattri A. Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment. Diseases 2022;10:114. [DOI: 10.3390/diseases10040114] [Reference Citation Analysis]
2 Lin S, Tan Z, Cui H, Ma Q, Zhao X, Wu J, Dai L, Kang H, Guan F, Dai Z. Identification of glycogene signature as a tool to predict the clinical outcome and immunotherapy response in breast cancer. Front Oncol 2022;12:854284. [DOI: 10.3389/fonc.2022.854284] [Reference Citation Analysis]
3 Liu J, Li M, Wu J, Qi Q, Li Y, Wang S, Liang S, Zhang Y, Zhu Z, Huang R, Yan J, Zhu R. Identification of ST3GAL5 as a prognostic biomarker correlating with CD8+ T cell exhaustion in clear cell renal cell carcinoma. Front Immunol 2022;13:979605. [DOI: 10.3389/fimmu.2022.979605] [Reference Citation Analysis]
4 Cui Y, Feng H, Liu J, Wu J, Zhu R, Huang R, Yan J. Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer. Front Mol Biosci 2022;9:1009168. [DOI: 10.3389/fmolb.2022.1009168] [Reference Citation Analysis]
5 Li J, Long Y, Sun J, Wu J, He X, Wang S, Wang X, Miao X, Huang R, Yan J. Comprehensive landscape of the ST3GAL family reveals the significance of ST3GAL6-AS1/ST3GAL6 axis on EGFR signaling in lung adenocarcinoma cell invasion. Front Cell Dev Biol 2022;10:931132. [DOI: 10.3389/fcell.2022.931132] [Reference Citation Analysis]
6 Zhou R, Liang J, Tian H, Chen Q, Yang C, Liu C, Miyamoto H. An Immunosenescence-Related Gene Signature to Evaluate the Prognosis, Immunotherapeutic Response, and Cisplatin Sensitivity of Bladder Cancer. Disease Markers 2022;2022:1-34. [DOI: 10.1155/2022/2143892] [Reference Citation Analysis]
7 Hugonnet M, Singh P, Haas Q, von Gunten S. The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology. Front Immunol 2021;12:799861. [PMID: 34975914 DOI: 10.3389/fimmu.2021.799861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Xu P, Zhang X, Cao J, Yang J, Chen Z, Wang W, Wang S, Zhang L, Xie L, Fang L, Xia Y, Xuan Z, Lv J, Xu H, Xu Z. The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviours through autophagy regulated by the FOXP2/MET/mTOR axis. Clinical & Translational Med 2022;12. [DOI: 10.1002/ctm2.707] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Selke P, Bork K, Zhang T, Wuhrer M, Strauss C, Horstkorte R, Scheer M. Glycation Interferes with the Expression of Sialyltransferases in Meningiomas. Cells 2021;10:3298. [PMID: 34943806 DOI: 10.3390/cells10123298] [Reference Citation Analysis]
10 Huang Z, Yan Y, Zhu Z, Liu J, He X, Dalangood S, Li M, Tan M, Cai J, Tang P, Huang R, Shen B, Yan J. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. Cell Death Dis 2021;12:537. [PMID: 34035231 DOI: 10.1038/s41419-021-03819-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
11 Pietrobono S, Stecca B. Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention? Cancers (Basel) 2021;13:2014. [PMID: 33921986 DOI: 10.3390/cancers13092014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]